Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma

Wu, Meng-Che; Chang, Hui-Chin; Jhang, Yi-Sheng; Gau, Shuo-Yan

doi:.0..

Letter to the Editor

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma

Meng-Che Wu^1,2,3, Hui-Chin Chang^3,4,5, Yi-Sheng Jhang⁶, Shuo-Yan Gau^7,8,9

¹Division of Pediatric Gastroenterology, Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan
²Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
³School of Medicine, Chung Shan Medical University, Taichung, Taiwan
⁴Evidence-based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan
⁵Library, Chung Shan Medical University Hospital, Taichung, Taiwan
⁶Department of Pharmacy, Chung Shan Medical University Hospital, Taichung, Taiwan
⁷Department and Graduate Institute of Business Administration, National Taiwan University, Taipei, Taiwan
⁸Department of Pharmacology, Chung Shan Medical University, Taichung, Taiwan
⁹Orthopedics Department, Chi-Mei Medical Center, Tainan, Taiwan

Correspondence :

Yi-Sheng Jhang ,
Email: vp45jknck5s@gmail.com

Received: August 18, 2024 Revised: August 29, 2024 Accepted: August 30, 2024

KeyWords: hepatocellular carcinoma; cohort study; epidemiology